Regencell Bioscience Holdings Limited
RGC
$12.80
$0.241.91%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -28.23% | -28.23% | -12.13% | -12.13% | 8.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.75% | -14.75% | -32.59% | -32.59% | -28.15% |
| Operating Income | 14.75% | 14.75% | 32.59% | 32.59% | 28.15% |
| Income Before Tax | 20.74% | 20.74% | 34.07% | 34.07% | 30.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 20.74% | 20.74% | 34.07% | 34.07% | 30.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -155.90% | -155.90% | 35.76% | 35.76% | 27.34% |
| Net Income | 15.46% | 15.46% | 35.97% | 35.97% | 31.41% |
| EBIT | 14.75% | 14.75% | 32.59% | 32.59% | 28.15% |
| EBITDA | 15.78% | 17.72% | 35.45% | 35.45% | 30.54% |
| EPS Basic | 14.81% | 14.81% | 36.36% | 36.36% | 30.77% |
| Normalized Basic EPS | 5.56% | 5.56% | -- | -- | 25.00% |
| EPS Diluted | 14.81% | 14.81% | 36.36% | 36.36% | 30.77% |
| Normalized Diluted EPS | 5.56% | 5.56% | -- | -- | 25.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | -0.07% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | -0.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |